Study | Country | Number of participants | Age | Metabolic risk criteria | Duration (weeks) | Medications | Findings |
---|---|---|---|---|---|---|---|
Alvarez et al. [40] | Chile | CON=13 RT=8 | CON= 40.1 ± 11.4 RT=33.9 ± 9.3 | Elevated glucose | 12 | NR | ↓HOMA-IR, FPG (p=0.011) with RT |
Dai et al. [47] | China | CON=35 RT=31 | CON=55–75 RT=55–75 | Prediabetes | 96 | Lipid lowering (3 CON, 6 RT) | ↓HbA1c, FPG (p<0.001), TC, LDL (p<0.001), TG (p=0.03), and ↑HDL (p<0.001) with RT |
Devallance et al. [48] | USA | CON=16 RT=14 | CON=51 ± 4 RT=51 ± 3 | Metabolic syndrome | 8 | Antihypertensive (41% CON, 38% RT). Cholesterol lowering (19% CON, 23% RT) | No significant changes in outcomes of interest |
Flández et al. [49] | Chile | CON=20 RT=20 | CON=46.47 ± 3.71 RT= 46.47 ± 3.71 | Metabolic syndrome | 12 | NR | ↓HbA1c (p<0.05) with RT |
Huffman et al. [50] | USA | CON=20 RT=20 | CON=18–70 RT=18–70 | Dyslipidemia | 24 | NR | No significant changes in outcomes of interest |
Finland | CON=40 RT=36 | CON=54 ± 1 RT=40–65 | Impaired glucose regulation | 12 | Lipid lowering (25% CON, 22% RT). Antihypertensive (30% CON, 33% RT). | No significant changes in outcomes of interest | |
Levinger et al. [51] | Australia | CON=15 RT=15 | CON=52.3 ± 5.8 RT=51.6 ± 7.1 | Metabolic risk factors according to the International Diabetes Federation | 10 | Antihypertensives, cholesterol lowering, and metformin. | No significant changes in outcomes of interest |
Levinger et al. [52] | Australia | CON=14 RT=15 | CON=51.21 ± 7.33 RT=51 ± 7 | Metabolic risk factors according to the International Diabetes Federation | 10 | Antihypertensives, cholesterol lowering, and metformin. | No significant changes in outcomes of interest |
Mager et al. [53] | Finland | CON=18 RT=14 | CON=60 ± 7 RT=60 ± 7 | Impaired fasting glucose and 2 metabolic syndrome factors | 33 | NR | No significant changes in outcomes of interest |
Marcus et al. [54] | USA | CON=6 RT=10 | CON=53.2 ± 6.5 RT=56.3 ± 6.4 | Impaired glucose tolerance | 12 | NR | No significant changes in outcomes of interest |
Stensvold et al. [55] | Norway | CON=11 RT=11 | CON=47.3 ± 10.2 RT=50.9 ± 7.6 | Metabolic syndrome | 12 | Antihypertensive and lipid lowering. (4 CON, 8 RT). | ↓WC with RT |
Turri-Silva et al. [56] | Brazil | CON=12 RT=19 | CON=51.21 ± 7.33 RT=51.42 ± 5.22 | Metabolic syndrome | 12 | NR | No significant changes in outcomes of interest |
Yuan et al. [44] | China | CON=83 RT=82 | CON=60.73 ± 5.83 RT=59.91 ± 5.92 | Prediabetes | 24 | Antihypertensives and cholesterol lowering. | ↓HbA1c (p<0.001), BMI, SBP (p<0.05) with RT |
Yan et al. [43] | China | CON=35 RT=35 | CON=60.31 ± 7.56 RT=62.06 ± 8.11 | Prediabetes | 24 | NR | ↓FPG (p=0.004) with RT |